Comparative Pharmacology
Head-to-head clinical analysis: IFEX versus TEPYLUTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IFEX versus TEPYLUTE.
IFEX vs TEPYLUTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IFEX (ifosfamide) is an alkylating agent that crosslinks DNA strands, inhibiting DNA synthesis and transcription. It requires hepatic activation via CYP3A4 to form active metabolites (ifosfamide mustard and acrolein).
Progestin that transforms endometrium from proliferative to secretory phase, inhibits gonadotropin secretion, and increases cervical mucus viscosity.
1.2 g/m2 intravenously daily for 5 consecutive days every 3 weeks, or 5 g/m2 as a 24-hour continuous infusion every 3 weeks.
100 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is approximately 15 hours in adults with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is 4-6 hours in healthy adults; prolonged to 10-15 hours in severe renal impairment.
Renal: approximately 50-70% of the administered dose is excreted in urine as unchanged drug; biliary/fecal excretion is minimal, accounting for less than 5%.
Primarily renal (70-80% unchanged) and fecal (15-20% as metabolites).
Category C
Category C
Alkylating Agent
Alkylating Agent